Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00412646
Status:
COMPLETED
Last Update Posted:
2010-04-28
First Post:
2006-12-15
Brief Title:
TMC125-C203 Phase II Randomized Patients Are Assigned Different Treatments Based on Chance Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients
Sponsor:
Organization:
Tibotec Pharmaceuticals Ireland
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
260
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: